S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
All the trading advice you’ve ever received boils down to this (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
All the trading advice you’ve ever received boils down to this (Ad)
Lacking counselors, US schools turn to the booming business of online therapy
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
All the trading advice you’ve ever received boils down to this (Ad)
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
All the trading advice you’ve ever received boils down to this (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
All the trading advice you’ve ever received boils down to this (Ad)
Lacking counselors, US schools turn to the booming business of online therapy
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
All the trading advice you’ve ever received boils down to this (Ad)
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
All the trading advice you’ve ever received boils down to this (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
All the trading advice you’ve ever received boils down to this (Ad)
Lacking counselors, US schools turn to the booming business of online therapy
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
All the trading advice you’ve ever received boils down to this (Ad)
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
All the trading advice you’ve ever received boils down to this (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
All the trading advice you’ve ever received boils down to this (Ad)
Lacking counselors, US schools turn to the booming business of online therapy
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
All the trading advice you’ve ever received boils down to this (Ad)

Oculis (OCS) Competitors

$9.99
+0.17 (+1.73%)
(As of 12/1/2023 ET)
Compare
Today's Range
$9.90
$10.35
50-Day Range
$9.10
$11.75
52-Week Range
$6.26
$14.50
Volume
3,547 shs
Average Volume
17,165 shs
Market Capitalization
$363.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$34.00

OCS vs. ORGO, BMEA, MRNS, IGMS, NATR, QURE, ANAB, CMPS, IMNM, and GRCL

Should you be buying Oculis stock or one of its competitors? The main competitors of Oculis include Organogenesis (ORGO), Biomea Fusion (BMEA), Marinus Pharmaceuticals (MRNS), IGM Biosciences (IGMS), Nature's Sunshine Products (NATR), uniQure (QURE), AnaptysBio (ANAB), COMPASS Pathways (CMPS), Immunome (IMNM), and Gracell Biotechnologies (GRCL). These companies are all part of the "pharmaceutical preparations" industry.

Oculis vs.

Organogenesis (NASDAQ:ORGO) and Oculis (NASDAQ:OCS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, community ranking, earnings, profitability, risk and institutional ownership.

Organogenesis has higher revenue and earnings than Oculis.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Organogenesis$450.89M0.80$15.53M$0.1027.30
Oculis$960K378.68-$40.55MN/AN/A

In the previous week, Organogenesis had 1 more articles in the media than Oculis. MarketBeat recorded 3 mentions for Organogenesis and 2 mentions for Oculis. Organogenesis' average media sentiment score of 1.36 beat Oculis' score of 1.29 indicating that Oculis is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Organogenesis
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Oculis
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Organogenesis received 82 more outperform votes than Oculis when rated by MarketBeat users. However, 78.57% of users gave Oculis an outperform vote while only 65.49% of users gave Organogenesis an outperform vote.

CompanyUnderperformOutperform
OrganogenesisOutperform Votes
93
65.49%
Underperform Votes
49
34.51%
OculisOutperform Votes
11
78.57%
Underperform Votes
3
21.43%

39.5% of Organogenesis shares are owned by institutional investors. Comparatively, 14.3% of Oculis shares are owned by institutional investors. 34.0% of Organogenesis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Organogenesis has a net margin of 2.90% compared to Organogenesis' net margin of 0.00%. Oculis' return on equity of 4.83% beat Organogenesis' return on equity.

Company Net Margins Return on Equity Return on Assets
Organogenesis2.90% 4.83% 2.88%
Oculis N/A N/A N/A

Organogenesis currently has a consensus target price of $3.75, suggesting a potential upside of 37.36%. Oculis has a consensus target price of $34.00, suggesting a potential upside of 240.34%. Given Organogenesis' stronger consensus rating and higher possible upside, analysts clearly believe Oculis is more favorable than Organogenesis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Organogenesis
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50
Oculis
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Organogenesis beats Oculis on 9 of the 15 factors compared between the two stocks.


Get Oculis News Delivered to You Automatically

Sign up to receive the latest news and ratings for OCS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OCS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OCS vs. The Competition

MetricOculisPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$363.52M$6.14B$4.72B$6.75B
Dividend YieldN/A2.94%2.87%4.79%
P/E RatioN/A8.1885.3912.35
Price / Sales378.68150.452,575.5058.35
Price / CashN/A19.1784.75138.86
Price / Book3.054.375.195.05
Net Income-$40.55M$202.13M$123.97M$177.19M
7 Day Performance3.85%4.79%2.69%2.67%
1 Month Performance1.94%4.68%5.22%5.64%
1 Year PerformanceN/A6.44%5.78%2.24%

Oculis Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ORGO
Organogenesis
2.8039 of 5 stars
$2.62
flat
$3.75
+43.1%
+0.4%$345.95M$449.01M26.201,030Positive News
BMEA
Biomea Fusion
1.8167 of 5 stars
$9.94
-0.3%
$43.88
+341.4%
+139.7%$354.96MN/A-2.98103Short Interest ↑
News Coverage
Gap Up
MRNS
Marinus Pharmaceuticals
2.1709 of 5 stars
$6.31
+0.2%
$20.72
+228.4%
+56.0%$344.34M$25.48M-2.38151Positive News
IGMS
IGM Biosciences
2.6201 of 5 stars
$5.80
+14.2%
$17.89
+208.4%
-70.3%$338.55M$1.07M-1.16290Short Interest ↓
NATR
Nature's Sunshine Products
2.2725 of 5 stars
$17.58
-1.2%
$21.50
+22.3%
+101.3%$335.43M$421.91M42.88800
QURE
uniQure
2.1416 of 5 stars
$6.98
-0.6%
$45.30
+549.0%
-72.6%$333.71M$106.48M-1.45501Short Interest ↑
ANAB
AnaptysBio
1.6454 of 5 stars
$13.85
-0.4%
$29.00
+109.4%
-45.1%$368.13M$10.29M-2.5696Analyst Report
CMPS
COMPASS Pathways
1.9224 of 5 stars
$5.98
-1.3%
$46.83
+683.2%
-45.6%$370.16MN/A-2.31181News Coverage
IMNM
Immunome
1.3624 of 5 stars
$7.67
-3.2%
$8.00
+4.3%
+77.3%$327.74MN/A-4.2437Positive News
GRCL
Gracell Biotechnologies
1.9749 of 5 stars
$4.50
-16.7%
$13.67
+203.7%
+60.3%$327.06M$60,000.00-4.29314Positive News
Gap Down
High Trading Volume

Related Companies and Tools

This page (NASDAQ:OCS) was last updated on 12/3/2023 by MarketBeat.com Staff

My Account -